ACOR : Summary for Acorda Therapeutics, Inc. - Yahoo Finance

U.S. Markets open in 3 hrs 38 mins

Acorda Therapeutics, Inc. (ACOR)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.25-0.05 (-0.20%)
At close: 4:00PM EST
People also watch
AMAGALNYACADBMRNACHN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close25.30
Open25.15
Bid20.30 x 200
Ask0.00 x
Day's Range25.05 - 25.55
52 Week Range16.40 - 37.36
Volume477,747
Avg. Volume732,524
Market Cap1.16B
Beta1.46
PE Ratio (TTM)-50.10
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors

    Acorda Therapeutics, Inc. today announced that Catherine D. Strader, Ph.D., has joined its board of directors, effective February 17. Dr. Strader is currently a founding partner at Synergy Partners R&D Solutions.

  • Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)
    Insider Monkey7 days ago

    Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)

    In order to ensure an extension of Ampyra’s protection to 2026, Acorda Therapeutics Inc (NASDAQ:ACOR) must fight off competition from competitors such as Roxane, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and Mylan NV (NASDAQ:MYL) as well as ensure it keeps its patents. This is according to Michael Yee, an RBC analyst. Ten companies have been sued […]

  • Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
    Capital Cube7 days ago

    Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017

    Categories: Yahoo Finance Get free summary analysis Acorda Therapeutics, Inc. reports financial results for the year ended December 31, 2016. Highlights Gross margins narrowed from 81.14% to 79.19% compared to the same period last year, operating (EBITDA) margins now -1.89% from 12.16%. Narrowing of operating margins contributed to decline in earnings. The table below shows the preliminary results ... Read more (Read more...)